Alopecia areata is an autoimmune condition characterized by non-scarring hair loss driven by a breakdown in hair follicle immune privilege. Management falls within dermatologic medicine and aims to modulate CD8+ T-cell activity around the hair bulb. Treatment protocols are stratified by disease severity, ranging from localized therapies for focal patches to systemic immunomodulators for extensive scalp and body hair loss.

Management starts with baseline assessment including dermoscopy and SALT scoring. Intralesional corticosteroids are administered via micro-injections (2.5–10 mg/mL triamcinolone acetonide) every 4–6 weeks directly into hairless patches. Systemic therapy involving oral JAK inhibitors (e.g., baricitinib 2–4 mg daily or ritlecitinib 50 mg daily) requires baseline lab testing (CBC, renal, liver, lipid panel, hepatitis B/C, and tuberculosis screening) with repeat testing at 4, 12, and 24 weeks. Topical immunotherapy involves weekly application and titration of diphenylcyclopropenone (DPCP) to induce mild contact eczema.

Evidence-based management of alopecia areata offers distinct clinical benefits depending on disease severity. Localized intralesional corticosteroid injections induce hair regrowth in up to 60–80% of focal patchy cases within 12 weeks. Systemic JAK inhibitors provide effective disease suppression for severe cases, achieving 80% scalp hair coverage (SALT score ≤ 20) in approximately 30–40% of patients with extensive hair loss. Early and tailored intervention halts disease progression, restores protective eyelash and eyebrow barriers, and significantly improves dermatologic quality of life scores.

Recovery in alopecia areata management refers to the timeline of hair follicle reactivation and terminal hair regrowth. Initial response is characterized by the appearance of fine, unpigmented vellus hairs within 6 to 12 weeks of initiating effective therapy. Pigmented, mature terminal hairs typically emerge between 12 and 24 weeks. Maximum clinical improvement is generally evaluated at 24 to 52 weeks. Ongoing maintenance therapy or periodic pulse treatments are frequently required to sustain hair density, as underlying autoimmune susceptibility persists.

Alopecia areata management addresses several clinical variants of autoimmune hair loss, including localized patchy alopecia areata, alopecia totalis (complete loss of scalp hair), alopecia universalis (complete loss of scalp and body hair), and ophiasis pattern hair loss (band-like loss along the scalp margins). It also addresses associated nail changes, such as trachyonychia and nail pitting, which often accompany severe autoimmune hair follicle involvement.

Pre-treatment evaluation includes clinical examination, trichoscopy, baseline laboratory tests (complete blood count, liver and renal function panels, lipid profile, and thyroid-stimulating hormone), and infectious disease screening (tuberculosis, hepatitis B, and hepatitis C) for systemic agents. Patients are instructed to discontinue scalp irritants 48 hours prior to topical applications or injections and to report any history of chronic or active infections.

Adverse effects vary by treatment modality. Localized injections may cause cutaneous atrophy, telangiectasia, pain, and folliculitis. Topical immunotherapy risks include severe contact eczema, lymphadenopathy, and post-inflammatory hyper- or hypopigmentation. Systemic JAK inhibitors carry risks of upper respiratory tract infections, acne, headache, elevated lipid parameters, creatine kinase elevations, and rare serious risks including serious infections, herpes zoster reactivation, major adverse cardiovascular events, and thromboembolism.

The clinical journey begins with a comprehensive dermatologic evaluation, including dermoscopy, scalp examination, and severity scoring using the Severity of Alopecia Tool (SALT). Following baseline laboratory screenings, an individualized protocol is selected, such as intralesional injections, topical immunotherapy, or oral JAK inhibitors. Treatment requires regular monitoring every 4 to 12 weeks to assess hair regrowth, manage adverse effects, and titrate dosages. Long-term management focuses on maintenance and rapid intervention during disease flares.